Reply to “IL28B polymorphism and hepatitis C: A genetic marker of peginterferon-α sensitivity devoid from classical interferon-α side effects?”  by Thompson, A.J. et al.
References
[1] Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic
variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Nature 2009;461:399–401.
[2] Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al.
IL28B is associated with response to chronic hepatitis C interferon-alpha and
ribavirin therapy. Nat Genet 2009;41:1100–1104.
[3] Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al.
Genome-wide association of IL28B with response to pegylated interferon-
alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:
1105–1109.
[4] Thompson AJ, Clark PJ, Singh A, Ge D, Fellay J, Zhu M, et al. Genome-wide
association study of interferon-related cytopenia in chronic hepatitis C
patients. J Hepatol 2012;56:313–319.
[5] McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al.
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C
infection. New Engl J Med 2009;361:580–593.
[6] Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Thrombocytopenia and the risk
of bleeding during treatment with peginterferon alfa and ribavirin for chronic
hepatitis C. J Hepatol 2010;53:455–459.
[7] Roomer R, Hansen BE, Janssen HL, de Knegt RJ. Risk factors for infection
during treatment with peginterferon alfa and ribavirin for chronic hepatitis C.
Hepatology 2010;52:1225–1231.
Hans Orlent⇑
Department of Gastroenterology and Hepatology,
AZ Sint. Jan AV, Bruges,
Belgium
Department of Gastroenterology and Hepatology,
Erasmus MC University Medical Center,
Rotterdam,
Netherlands⇑Corresponding author. Address:Department of Gastroenterology
and Hepatology, AZ Sint. Jan AV, Ruddershove 10, 8000 Brugge,
Belgium.
Fax: +32 50 452179.
E-mail address: Hans.Orlent@azbrugge.be
Robert J. de Knegt
Harry L.A. Janssen
Department of Gastroenterology and Hepatology,
Erasmus MC University Medical Center,
Rotterdam, Netherlands
Letters to the EditorReply to ‘‘IL28B polymorphism and hepatitis C: A genetic marker
of peginterferon-a sensitivity devoid from classical
interferon-a side effects?’’To the Editor:
We appreciate the interest of Orlent et al. in our recent study
[1] and would like to comment on the issues raised in their
letter.
(i) The primary endpoint we selected for all genome-wide
analyses of peginterferon (pegIFN)-induced cytopenia
was quantitative reduction in cell counts, as a continuous
variable, at week 4. We chose the continuous variable as
the primary endpoint for two reasons. Firstly, this method
maximizes the statistical power of the dataset. Secondly, it
avoids the pitfalls of deﬁning pre-speciﬁed thresholds for
cytopenia, where timing and the chosen level of the
threshold are arbitrary. We chose the week 4 timepoint
to minimize confounding by dose adjustment/adherence.
It is true that week 4 preceded the nadir for pegIFN-related
thrombocytopenia and neutropenia in this study, which
occurred between week 8 and 12. However, the rate of
decline was most profound in the ﬁrst 4 weeks, with sig-
niﬁcant reductions in both platelet counts and neutrophil
counts by week 4 [1]. We have subsequently tested for
association between the IL28B polymorphism rs12979860
and quantitative reduction of platelet/neutrophil counts
at week 12. No signiﬁcant association was observed.
(ii) Orlent et al. suggested that inclusion of patients treated
with low-dose pegIFN-a-2b in our analysis may have
confounded the results. We included these patients to
maximize the sample size. We did adjust for pegIFN dose
however, as stated in the methodology [1], by coding a
binary variable for full vs. low dose pegIFN. This variable
was included in all statistical models. PegIFN dose
was signiﬁcantly associated with both thrombocytopenia
and neutropenia as expected. IL28B polymorphism was742 Journal of Hepatology 2012not signiﬁcantly associated with pegIFN-cytopenia when
analysis was limited to patients receiving full-dose
pegIFN.
(iii) Orlent et al. also raised the possibility of inclusion bias. It
is true that we limited the analysis of week 4 cytopenia to
patients who were at least 80% adherent to study treat-
ment to this timepoint. This decision was taken to reﬁne
the clinical phenotype. However, it should be noted that
only 26 patients were excluded from the analyses of
platelet/neutrophil counts on the basis of adherence at
the week 4 timepoint [1]. Inclusion of these 26 patients
into the analysis does not change the results of the anal-
yses. The majority of the patients who consented to
genetic testing, but were not included in this analysis,
were excluded on the basis of genotyping quality control
or missing data points (only patients with complete data-
sets for all relevant variables could be included in the
analyses). There was no signiﬁcant difference in the
median reductions of platelet counts or neutrophil counts
comparing patients who were included in the ﬁnal analy-
sis vs. patients who consented to genetic testing but were
not included in the ﬁnal analyses (patients of European
American, African American and Hispanic ethnicity con-
sidered separately). We therefore feel that inclusion bias
within this study was unlikely. We have recently ana-
lyzed the overall IDEAL cohort for patient factors that
might inﬂuence consent to the performance of genetic
testing and the data will be presented at AASLD 2011
[2]. There were no differences in treatment outcomes or
overall adverse events (including cytopenia) between
patients who did, or did not consent, to participation in
the pharmacogenomics substudy.vol. 56 j 738–747
The data suggest that IL28B polymorphism does not inﬂuence
the occurrence or severity of IFN-related cytopenia. However, we
acknowledge that the methodology of genome-wide association
studies has some limitations, including the statistical require-
ment to correct for multiple testing. As a consequence, small
effect sizes may not be detected. Therefore, we cannot exclude
the possibility that there may be a small contribution (odds ratio
<1.5) of common genetic variants to IFN-related cytopenias. The
clinical importance of such a contribution would be expected to
be modest.
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is due to metabolic overlo
To the Editor:
In a recent publication Miura et al. reported on the mechanism of
cholestasis after partial hepatectomy (PH) in rats [1]. The ﬁrst day
after PH, they ﬁnd a transient doubling of serum bile salts, a
down-regulation of the bile acid uptake protein Ntcp and an
up-regulation of Mrp4 and Cyp7A1. With these ﬁndings they con-
ﬁrm a number of earlier studies [2–4]. Miura et al. consider this as
evidence of cholestasis. We like to take issue with this view.
Vos et al. (in 1999) showed that 24 h after PH in rats, bile ﬂow,
expressed per gram of liver, was increased from 1.5 ± 0.1 to
2.6 ± 0.4 ll/g liver/min. Bile ﬂow per 100 g body weight did not
change. The same is true for bile salt secretion; it increased from
80 ± 4 to 152 ± 22 nmol/g liver/min and did not change when cal-
culated per 100 g body weight [2]. Other authors have reported
similar ﬁndings both in rats and mice [5,6]. Thus, if cholestasis
is deﬁned as an impairment of bile ﬂow, there is no cholestasis
after PH. To the contrary, for the remnant liver there is increased
bile ﬂow and bile salt ﬂux. The remnant liver maintains a normal
bile ﬂow despite a decrease of organ mass. The transiently ele-
vated serum bile salt levels may be the consequence of de novo
bile salt synthesis. Thus, elevated serum bile salt and bilirubin
levels not always mean cholestasis but they can be a sign of
hepatic overload. This is not a trivial statement because this over-
load has profound physiological consequences in that it may trig-
ger hepatic regeneration. This is in line with the metabolic
overload theory as a trigger of liver regeneration [7]. There is
ample new evidence that bile salts are instrumental for this
response [8,9].
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Predictors of consent to pharmacogenomics testing in the IDEAL study.
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JOURNAL OF HEPATOLOGYsalts after partial hepatectomy
ad and not to cholestasis
Bile salts are ligands for the nuclear hormone receptor FXR.
Activation of FXR in the liver simulates regeneration. In agree-
ment with this, FXR/ mice show delayed liver regeneration
after PH [10]. Although the precise mechanism has not been clar-
iﬁed yet, this activation depends on the intracellular free concen-
tration of bile salts and this depends in part on a balance between
hepatic uptake, secretion and de novo synthesis. The ﬁndings of
Miura et al. and others suggest that uptake is impaired and baso-
lateral secretion is increased. This, together with data showing
that canalicular secretion is increased, makes it difﬁcult to predict
what happens to the intracellular bile salt concentration but a fair
guess would be that there would have been no change if de novo
synthesis would not have been activated. Indeed, Csanaky et al.
reported that after PH in mice, the hepatic concentrations of gly-
cine-conjugated and unconjugated bile salts were increased [6].
Up-regulation of Cyp7A1 is most likely responsible for the
increased serum and liver bile salt levels and we suggest that this
is a key event in the regenerative response of the liver. Cyp7A1
expression is mainly controlled by a protein called Fgf15 that is
produced in the ileum and acts on the FGFR4 receptor in the liver.
In the ileum, Fgf15 synthesis is activated by binding of bile salts
to FXR. Since bile salt ﬂux through the ileum after partial hepa-
tectomy is not decreased, we propose that FGFR4 in the liver
may be down-regulated in order for Cyp7A1 to be up-regulated.
In conclusion: in order for bile salts to play a controlling role, bile
salt ﬂux through the liver has to be maintained within very strict
limits. This is achieved by a detailed regulation of uptake,
secretion and synthesis. These regulations are probably more
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